Variables Summary, n=75
Age (yrs), median (IQR) 34 (25-43)
Gender, n (%):
Male 41 (54.67)
Female 34 (45.33)
Median CD4T cell count, cells/µL  (IQR) 149 (113-231)
Median Viral load, log10 copies/mL  (IQR) 5.34 (4.19-5.82)
Risk Exposure, N (%)
Heterosexual (%) 35 (46.67)
Bisexual (%) 26 (34.67)
MSM (%) 14 (18.67)
Other co-infections, n (%): 26 (34.67)
Treatment Regimen, N (%)
AZT, 3TC, EFV 21 (28.00)
AZT, 3TC, NVP 17 (22.67)
TDF, 3TC, NVP 23 (30.67)
TDF, 3TC, EFV 14 (18.67)
IQR: Interquartile Range; MSM: Men who have Sex with Men; AZT: Zidovudine; 3TC: Lamivudine; EFV: Efavirenz; NVP: Nevirapine; TDF: Tenofovir
Table 1: Demographic characteristics and laboratory results of the clinical study panel